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Abstract
Across neurodegenerative diseases, common mechanisms may reveal novel therapeutic targets based on neuronal
protection, repair, or regeneration, independent of etiology or site of disease pathology. To address these mechanisms
and discuss emerging treatments, in April, 2021, Glaucoma Research Foundation, BrightFocus Foundation, and the
Melza M. and Frank Theodore Barr Foundation collaborated to bring together key opinion leaders and experts in the
field of neurodegenerative disease for a virtual meeting titled “Solving Neurodegeneration”. This “think-tank” style
meeting focused on uncovering common mechanistic roots of neurodegenerative disease and promising targets for
new treatments, catalyzed by the goal of finding new treatments for glaucoma, the world’s leading cause of irreversi‑
ble blindness and the common interest of the three hosting foundations. Glaucoma, which causes vision loss through
degeneration of the optic nerve, likely shares early cellular and molecular events with other neurodegenerative dis‑
eases of the central nervous system. Here we discuss major areas of mechanistic overlap between neurodegenerative
diseases of the central nervous system: neuroinflammation, bioenergetics and metabolism, genetic contributions, and
neurovascular interactions. We summarize important discussion points with emphasis on the research areas that are
most innovative and promising in the treatment of neurodegeneration yet require further development. The research
that is highlighted provides unique opportunities for collaboration that will lead to efforts in preventing neurodegen‑
eration and ultimately vision loss.
Keywords: Neurodegeneration, Alzheimer’s Disease, Glaucoma, Parkinson’s Disease, Huntington’s Disease, Genetics,
Metabolic stress, Neuro-regeneration, Neuro-replacement, Neurovascular coupling, Biomarker, Cell-replacement,
Detection, Glia, Imaging, Model Systems, Organoids
Background
A wide spectrum of neurodegenerative disorders affects
the central nervous system (CNS), causing a breakdown in connectivity and communication between
neurons integral to sensory, motor, and cognitive processes including vision, hearing, movement, speech and
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language, memory, and others. This breakdown in neuronal connection is characterized by the progressive
degradation of synapses and axons that lead to eventual
neuronal death. Cases of neurodegeneration and dementia worldwide are predicted to rise dramatically with the
aging population, posing a significant threat to global
healthcare systems [1,2]. Although neurodegenerative
diseases are highly complex and can be etiologically distinct, uncovering commonalities in disease mechanisms
and pathologies may yield a deeper understanding of
the triggering events in neurodegeneration and generate
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opportunities for novel pan-neurodegenerative therapeutic avenues.

Main text
Etiological features of neurodegenerative disorders
Alzheimer’s disease and related dementias

The symptoms associated with neurodegenerative disease are largely dependent on the CNS tissue affected,
which varies across diseases such as Alzheimer’s Disease
(AD), Huntington’s Disease (HD), Parkinson’s Disease
(PD), and Amyotrophic lateral sclerosis (ALS). Although
each neurodegenerative disease is distinct in terms of etiology, severity, and rate of progression, shared molecular changes and mechanisms can be identified offering
potential avenues for research across multiple diseases.
Alzheimer’s Disease represents the most common form
of dementia, predominantly afflicting the aged population [3]. Over time, patients develop gradual but progressive memory loss and cognitive decline associated
with the degeneration of neurons [4]. In AD, severity of
symptoms is correlated with pathophysiological events
caused by protein aggregations in the cerebral cortex
[5–8]. These have been shown histologically as the deposition of β-amyloid (Aβ) aggregated fibrils and plaques,
and neurofibrillary tangles containing hyperphosphorylated Tau protein [5]. Amyloid precursor protein (APP)
can be cleaved to form varying lengths (from 38 to 43
amino-acids) of Aβ peptides [9]. Aβ monomers can bind
to one another to eventually form oligomers and insoluble plaques. The deposition and accumulation of Aβ oligomers is generally accepted as central to pathogenesis of
AD and the most toxic to neurons; however, other pathological events such as tau aggregation, as well as neuroinflammation also play a major role and contribute to
synaptic loss and neurodegeneration [3].
While AD accounts for 60–80% of dementia cases, vascular cognitive impairment and dementia (VCID) are the
second leading cause of dementia [10]. Recent mounting evidence supports an underlying vascular element
in the pathophysiology of AD [11]; abnormal microvasculature in AD patients is present post-mortem in the
brains of patients [11–13]. In fact, the role of cerebrovascular alterations in dementia-associated neurodegenerative diseases has been highlighted as a primary cause of
cognitive impairments and as a factor that contributes
directly to dementia associated with neurodegeneration
[14, 15].
PD, the second most common form of neurodegenerative disorder [16], is also characterized by progressive loss of neurons. Neurodegeneration in PD leads to
the impairment of basal ganglia in the brain, presenting in the clinic as difficulty with motor-movement,
cognitive impairment, autonomic failure and other
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neuropsychiatric symptoms [17]. Similar to AD, PD
symptoms also correlate with aggregates of misfolded
protein, in this instance α-synuclein, leading to the subsequent formation of Lewy bodies [18]. PD falls under an
umbrella of synucleinopathies which also include multiple system atrophy and dementia with Lewy bodies [19].
Among neurodegenerative disorders, ALS is the most
rapid to progress to fatality; where PD and AD symptoms
can begin in a prodromal period that can last many years,
ALS can begin and span to death in under 2–3 years [20].
ALS manifests as widespread motor neuron abnormalities involving the brain, spinal column and peripheral
neuromuscular system; speech impairment, difficulty
swallowing followed by progressive paralysis of the arms
and legs are common [20]. Progress in therapeutics for
ALS patients is slow due to the complexity and heterogeneity of disease mechanisms. Some 15% of ALS cases
are familial can be directly attributed to disease-causing alleles of genes such as SOD1, TARDBP, FUS, and
OPTN [20]. Pathological mechanisms in ALS include
metabolic impairment (gross mitochondrial morphological and functional changes), glutamate-induced excitotoxicity, and neuroinflammation [20]. Again, in line with
other neurodegenerative diseases, ALS pathophysiology
also includes protein aggregation, this time of the TAR
DNA-binding protein 43 (TDP43) which can occur in
sporadic and familial forms of ALS [21].
The etiologies of AD, PD, ALS, and other related
dementias are highly complex. In addition to the pathophysiological changes seen post-mortem, such as deposition of insoluble protein aggregations, there are
overlapping and common mechanisms of neurodegeneration that include neuroinflammatory, metabolic, neurovascular, and genetic factors.
Neurodegeneration of the visual system

Glaucoma is the leading cause of irreversible blindness
worldwide [22]. The disease encompasses a group of
optic neuropathies that lead to the progressive degeneration of retinal ganglion cells (RGCs), the output neurons of the retina, along with their axons which form the
optic nerve - the sole neuronal projection to the brain’s
higher vision centers. Like many other neurodegenerative diseases, glaucoma is associated with increasing age;
as our population ages, it is estimated that approximately
112 million people will be affected worldwide by 2040
[23]. Besides age, elevation in intraocular pressure (IOP)
is amongst other prominent risk factors for the disease
which include race, severe myopia, central corneal thickness, and genetic predisposition to congenital glaucoma.
Forms of glaucoma are classified clinically according to
a key anatomic feature of the anterior segment, the iridocorneal angle, which is defined by the angle formed where
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the iris and cornea meet. In the most prevalent form of
the disease, primary open-angle glaucoma (POAG), the
angle is open but there is a progressive resistance within
the aqueous humor outflow pathways that gradually leads
to an increase in IOP. However, not all glaucoma patients
suffer from elevations in IOP; normotensive glaucoma
patients never experience increases in IOP [24, 25] and
conversely some patients with extremes in IOP at risk for
glaucoma do not exhibit neurodegeneration [26]. IOP
remains the only treatable risk factor, and although interventions in the clinic such as IOP-lowering drops or IOPlowering surgery are available, many patients progress
with neurodegeneration of the visual projection despite
treatment [27]. As advances are made in research we are
beginning to understand that glaucoma is characterized
by the sensitivity of the optic projection to IOP, rather
than IOP itself [27]. How this sensitivity begins or evolves
throughout disease progression, or which IOP-independent mechanisms are at play remain to be determined but
may hold the key to early detection and prevention in the
disease.
The optic nerve head (ONH), where over 1.5 million
unmyelinated RGC axons converge to exit the globe
and form the optic nerve proper in humans, is a critical
juncture for pathogenic neurodegenerative processes
that occur in glaucoma. The vulnerability of axons at
this site is by virtue of the unique structure and physiology of the ONH [28–31]. There, a complex interplay
is seen between neuronal, glial, vascular, and biomechanical components that can change with age to influence sensitivity of the optic projection to any given IOP
[28, 29, 32, 33]. All tissues in the human body show natural variations in stiffness, and changes in this stiffness
occur naturally with aging, but can also be exacerbated
as a result of inflammatory events (i.e., increased deposition of collagen and extracellular matrix components
by cells, or proliferation of glia, namely astrocytes). In
addition, remodeled tissue and increased stiffening act
as environmental cues to further drive inflammation
[34]. There appears to be an interplay between inflammation and cellular biomechanics that may be relevant
in glaucoma and tissues of the ONH [34]. Changes in
the retina and ONH associated with mechanosensitivity [35, 36], as well as alterations in ocular stiffness
with age [37], have been independently investigated in
glaucoma pathogenesis, along with extracellular matrix
deposition due to inflammation. Making the connection between tissue biomechanics and inflammation
as a key molecular driver of pathogenesis may uncover
novel areas of therapeutic intervention in glaucoma. It
is also becoming apparent, in a range of neurodegenerative diseases, that the immune and glial responses
are not dependent on any one genetic mutation or
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predisposition for disease – making understanding of
these mechanisms important for all patients.
The variety in etiology of glaucoma combined with the
ineffectiveness of IOP-lowering drugs for many patients
suggests multiple mechanisms of neurodegeneration.
By considering glaucoma a neurodegenerative disease,
research into the triggers (i.e., early molecular events)
and drivers of neurodegeneration can identify novel
areas of therapeutic intervention to preserve and restore
vision. In addition, the optic projection is an accessible
extension of the CNS that allows investigators to directly
visualize CNS neurons and define mechanisms that may
be leveraged for understanding other neurodegenerative
diseases.
Mechanisms of progression

It is no coincidence that as humans age, so too does the
incidence of neurodegenerative disease as homeostatic
cellular mechanisms begin to malfunction, and new cellular functions associated with diseases arise. Neurodegeneration involves complex interactions between
adjacent cells and their axonal projections; neurons have
both proximal and distal regions that have distinct cellular environments and in turn distinct mechanisms of
disease pathology. Furthermore, the CNS does not always
act in isolation; the peripheral nervous system (PNS) and
peripheral immune system are increasingly implicated as
active players in the degeneration of the CNS. Identifying molecular commonalities will enhance understanding of neurodegenerative events, which could then be
harnessed in the design of broad-stroke therapeutics for
neurodegenerative mechanisms across multiple diseases.
To reach this goal of broadly applicable therapeutics for
neurodegenerative disease some knowledge gaps remain:
(i) common molecular events in the early stages of disease progression, i.e., triggering events that tip the scale
in an amplification cascade that leads to neurodegeneration, (ii) events in progression that catalyze already
existing neurodegenerative events, (iii) which cell types
are involved, (iv) common pathological endpoints, i.e.,
how can we back-track from these events to prevent or
replace diseased tissue, and finally (v) discerning which
events are pro-degenerative vs. reparative or even proregenerative. As a collective, we have identified several
common mechanistic areas of focus that may provide
potential pan-neurodegenerative therapeutic strategies. These include: environmental factors, neuroinflammation, metabolic stress, neurovascular coupling, and
genetic contributions to disease (Fig. 1).
Environmental contributions to neurodegeneration

Environmental factors can have a profound impact
on cellular and epigenetic contributions to disease
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Fig. 1 Common mechanisms of neurodegeneration. Across neurodegenerative diseases, five main areas of mechanistic overlap exist, these
include: (1) environmental factors such as diet, age, and, exercise; (2) metabolic stress, e.g., mitochondrial dysfunction, increased reactive oxygen
species (ROS); (3) genetic contributions, e.g., genome-wide association study-linked risk alleles (GWAS), sex-linked genetic contributions; (4)
neurovascular coupling, e.g., breakdown of the blood-brain-barrier and dysfunctional neurovascular coupling and; (5) neuroinflammation, e.g.,
infiltration of peripheral immune cells, and increased glial reactivity. Environmental factors contribute to all mechanistic areas of degeneration

progression. For example, these factors include age, diet,
exercise, and exposure to neurotoxic substances that can
act to trigger and/or exacerbate underlying neurodegenerative events. As such, environmental factors play
a role in many of the shared degenerative mechanisms
discussed below. Across many diseases, age is a primary
risk factor and tissues that are comprised of postmitotic
cells, such as neurons in the brain and retina, are particularly sensitive to the effects of aging [38]. Hallmarks
of aging cells include genomic instability, epigenetic
alterations, dysregulated signaling pathways, and mitochondrial dysfunction. Changes that occur with age can
impact homeostatic functions in cells, rendering them
sensitive to neurodegeneration. Other external factors,
such as diet and exercise, are proving to be crucial factors in maintaining CNS health [39, 40]. Micronutrients,
such as vitamins and trace elements are integral to many
key biological processes, such as mitochondrial ATP
production and immune responses, which in turn affect

CNS physiology [39]. Recognizing the role that external
factors play in degeneration and the impact on cellular
mechanisms as outlined blow (i.e., signaling pathways
such as neuroinflammation, metabolism, mitochondrial
dysfunction), will help to provide novel therapeutic strategies for neurodegenerative diseases.
Neuroinflammation

Inflammatory events that influence the CNS (what is
sometimes referred to as “neuroinflammation”) have
multifaceted outcomes, which can be neuro-protective,
neuro-regenerative and neurodegenerative, defined by
location, timing, and duration. Inflammation outside of
the CNS involves the infiltration of circulating monocytes and other immune cells, whereas inflammation
within the CNS is usually (but not always) independent
of peripheral inflammatory infiltration and involves resident glia, such as microglia and astrocytes [41]. Neuroinflammation in neurodegenerative disease was always
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assumed to be merely a response of the system to other
pathophysiological events. However, emerging data from
preclinical and clinical studies across a range of neurodegenerative diseases including AD, PD and Huntington’s
Diseases, ALS, and multiple sclerosis, among others,
have established that immune-mediated events can trigger and drive pathogenesis [42–45].
Increasing age is associated with increased low-grade
chronic inflammation, or inflamm-aging [46] due to dysregulation of immune [47], glia [48, 49], or metabolic
homeostasis [50]. In humans, age leads to elevations in
circulating inflammatory markers such as C-reactive
protein [51] and inflammatory cytokines [52, 53]. Dysfunctional inflammatory responses that occur with aging
alone may act to induce or simply aggravate inflammatory events already underway in neurodegeneration.
Such dysfunction in immune surveillance (usually conducted by microglia and astrocytes) that occurs with age
may be the instigator in triggering prolonged inflammation. In AD, a hallmark of disease pathology is the presence of neuroinflammation in the brain, which appears to
manifest as reactive responses by astrocytes and microglia [54]. Elevation in pro-inflammatory cytokines in the
brains of AD patients leads to an accumulation of Aβ
and Tau plaques which ultimately result in neuronal loss
[55–57]. Neuronal injury due to accumulating Aβ exists
in a perpetuating cycle whereby production of inflammatory cytokines causes release of neurotoxic Aβ, which
in turn triggers reactive microglia to release more proinflammatory cytokines [56, 58]. In AD, microglia are
the primary cell type that engulfs and proteolyzes neurotoxic Aβ [3]. Since Aβ plaques are difficult to break down,
the efficiency of the microglial clearance dissipates with
time leading to increased amyloid and enhanced release
of pro-inflammatory cytokines [57]. As such, microglial
responses are likely neuroprotective in the early stage but
neurotoxic in the late stage of AD [59].
In humans, inheritance of the apolipoprotein E ε4
(APOE4) allele strongly increases the chance of developing AD [60]. The reactive response of microglia and
astrocytes in the brain is increased in human patients
and mouse models expressing the APOE4 allele. APOE4
alters the baseline pro-inflammatory response even in the
absence of disease, suggesting that APOE4 may indeed
cause dysfunctional inflammatory responses that trigger neurodegeneration [61–63]. Furthermore, APOE4
is correlated with dysfunctional microglial clearance of
Aβ [64]. Although the majority of people carrying the
APOE4 genetic variant have an enhanced predisposition
for AD, the effect size is lower or absent in populations of
people with African ancestry compared with Europeans
or Chinese [65]. For example, some South American nonindustrialized populations appear to benefit from APOE4
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in order to survive parasitic infection in early childhood,
with no apparent adverse AD-associated effects in aged
individuals [66].This lack of association of the allele with
disease highlights how genetic variation, environmental
factors and epigenetics may affect gene-associations of
disease.
Similarly, in age-related macular degeneration (AMD)
and glaucoma, APOE4 is protective against the disease
[67, 68]. The reason why this inverse relationship is seen
in retinal disease and a positive correlation with disease is
seen in AD is intriguing. In a mouse model of AMD, mice
with the human APOE4 variant had less reactive microglia [69]. Reactive microglia in the retina are already
proven to be pathological in glaucoma, so perhaps lessreactive glia in the retina are protective in the case of
APOE4 variants whereas dysfunctional microglia in AD
are detrimental. A deeper understanding of evidence
across disease pathologies like this that will enhance our
understanding of glaucoma as a neurodegenerative disease and will allow us to understand how neuroinflammatory events contribute to disease pathology across the
spectrum of human populations.
Not all disease-linked mutations cause direct responses
from cells to increase inflammatory mediators. In ALS
patients, harboring genetic mutations in the superoxidase
dismutase enzyme (SOD1) accounts for about 5% of ALS
cases. These mutations do not alter the basal microglial
or astrocyte transcriptome, but instead drastically lower
the astrocyte threshold to inflammation making them
poised to respond faster and more aggressively [70]. Such
studies highlight the importance of investigating prodromal and secondary inflammatory responses and functions in cells expressing disease-associated mutations.
In PD, similarly to AD, protein aggregations are a key
pathological element; post-mortem examination has
identified aggregations of α-synuclein in Lewy bodies of
patients with the disease [71]. These protein aggregates
that accumulate in the neurons of the substantia nigra
are unable to be cleared, triggering neurodegeneration.
Since the discovery of high numbers of reactive microglia
in postmortem brain tissue of PD patients, it has been
suggested that neuroinflammatory events could be the
initial instigator of pathogenic mechanisms in PD [72].
Like dysfunctional neuroinflammatory mechanisms in
AD, the same “missing-link” question can be posed for
PD: are neuroinflammatory events responsible for misfolding of proteins, i.e., triggers of the disease, or are they
secondary to protein aggregations? Interestingly, there
have been studies correlating the use of non-steroidal
anti-inflammatory drugs (NSAIDs) with the prevention
or delay of PD [73]. Similarly, the glucagon-like 1 peptide receptor agonist, NYL01, originally developed to
combat inflammation in diabetes, has proved beneficial
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in limiting microglia cytokine release and astrocyte
reactivity in mouse models of PD [74], as well as in the
bead-occlusion model of glaucoma [75]. These findings highlight neuroinflammation and systemic immune
responses as active contributors to progression of disease
and the importance of understanding crosstalk between
the CNS, PNS and vascular system in disease. Below we
discuss the role of additional factors such as mitochondrial pathology, in diseases such as PD.
While these results suggest that NSAID reduce systemic inflammation associated with PD progression, they
do not resolve why, in general, anti-inflammatory therapy
for neurodegenerative diseases often ends up fruitless.
Indeed, anti-inflammatory or antioxidant therapies for
neurodegenerative diseases in clinical trials have often
been disappointing. An important factor in the role of
neuroinflammation in neurodegeneration is timing. It is
possible that neuroinflammatory responses have a time
and a place for beneficial effects, yet drastic detrimental
effects when activated and persisting at the wrong time
in disease.
Until recently glaucoma was not considered an inflammatory disease largely due to the supposed immune
privilege state of the retina arising from the blood-retinalbarrier (BRB). However, there is accumulating evidence
to the contrary in studies from both animal models of
the disease and in human patients [76, 77]. Most of our
understanding of how the immune system responds in
glaucoma has been derived from animal models where
onset of elevated IOP leads to early and almost immediate
increase in microglial activation and reactivity [78–83].
In post-mortem tissue from human patients, reactive
microglia in the ONH are evident [84, 85]. Inflammation in glaucoma appears to be paradoxical; there is a
basal level of intrinsic immune surveillance and reactivity that is required to maintain homeostasis, which can
even stimulate regeneration (see below) and yet, too much
stimulation of inflammatory pathways is associated with
degenerative events. In the retina and optic nerve, resident glia (microglia, astrocytes, and Müller glia) act as the
immune surveillance and maintain homeostasis by clearing cellular debris, releasing neuroprotective factors, and
maintaining homeostasis [86, 87]. A sudden insult, such
as an increase in IOP can tip the balance and trigger resident glia to adopt a reactive pro-inflammatory, degenerative state. In addition to resident immune surveillance,
there is clinical evidence of transient optic disc microhemorrhages in patients independent of IOP, indicating a
clear breach of the blood-retinal-barrier (BRB) and infiltration of circulating immune cells that are associated
with disease progression [88–94].
The infiltration of circulating immune cells through
BRB rupture may also lend some explanation to an
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autoimmune component of the disease seen in animal
models and human patients [95]. Serum auto-immunoglobulins against heat-shock proteins (HSPs) have
been found in the retina of animals and humans with
glaucoma, and inoculation of rodents with HSP60 and
HSP27 induces optic neuropathy [96, 97]. A link between
IOP elevation, intact commensal microflora, and T-cell
activation may in part explain HSP-derived autoimmune reactivity. Gut microbiome-sensitized 
CD4+
T-cell infiltration into the retina promotes the progressive degeneration of the retina and optic nerve after
microbead-induced IOP elevation [98]. After IOP insult,
T cells specifically reactive to HSPs infiltrate the retina;
germ-free mice did not show any evidence of neurodegeneration after IOP elevation [98]. These results provide
evidence that T cells reactive to host microflora mediate
prolonged degeneration of the optic nerve after injury.
How circulating immune cells affect resident glial
responses and to what extent factors released by these
cells encourage neurodegeneration remain uncertain. It
is possible that infiltrating cells could promote regeneration of cell processes lost by acute retinal inflammation.
In the PNS, the innate immune response to injury plays
an essential role in enabling sensory and motor neurons to regenerate axons back to their peripheral targets
[99]. Interestingly, a spike in IOP can also cause an initial influx of macrophages and neutrophils that express
molecules (e.g., oncomodulin and SDF1) that can initially stimulate growth of the axon [100–103], leading to
the questions of what determines cellular release of proregenerative molecules vs. pro-degenerative molecules
under stress conditions and whether there are cells that
can be coaxed towards pro-regenerative states through
release of specific inflammatory factors. In glaucoma,
involvement of the inflammatory response in disease
progression is indisputable, but more research into the
pleiotropic role of immune cells is warranted.
Increasing knowledge of the role of astrocytes and
microglia in disease has led to the identification of a proreactive sub-state of astrocytes (triggered by reactive
microglia) that play a key role in driving retinal degeneration by release of toxic lipids [104, 105]. Astrocytes have
been identified as important early responders to unilateral IOP elevation and optic nerve injury by redistributing metabolic resources to the site of injury to promote
optic nerve health [106]. Understanding how reactive
astrocyte sub-states can drive disease states, or play protective roles, is fundamental to advancing our understanding of inflammation in disease.
Metabolic stress

The energy produced by mitochondria (in the form of
adenosine triphosphate; ATP) is required for synthesis
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of neurotransmitters, bidirectional axonal transport, restoration of ion gradients, buffering of calcium and the
organization of synaptic vesicles, among other functions
[107]. Mitochondria are highly dynamic organelles, and
continuously change their size, shape, number, and cellular location to meet metabolic demands of neurons. In
addition, mitochondrial fusion, and fission are important
for the inheritance of mitochondrial DNA. There are several important processes that mitochondria can undergo
to meet metabolic demands; however, they can become
dysfunctional in disease [108]. Mitochondrial biogenesis
describes the biosynthetic process of increasing mitochondrial number [107], while a delicate balance between
fusion and fission allows for the rapid adaptation to meet
metabolic demands [107, 109]. Mitophagy, or mitochondrial degradation and clearance is also imperative to
maintain cellular homeostasis. Finally, mitochondria are
transported along the length of neuronal axons to synaptic terminals and dendrites to provide energy at different
focal locations along the neuron 107.
Besides the inheritance of genes that can cause mitochondrial disease, increasing age increases spontaneous
mutation of mtDNA [110]. Aging can also cause mitochondria to function less efficiently, which results in elevated production of reactive oxygen species (ROS), that
in turn can trigger further mtDNA mutation, pro-inflammatory signaling, and protein dysfunction. ROS production is an unavoidable byproduct of aerobic respiration
along the electron transport chain, and complexes I and
III account for up to 90% of cellular ROS production
[111]. Although ROS are important for cellular signaling,
an imbalance leave mitochondria dysfunctional and less
efficient at producing ATP. In addition, ROS can cause
lipid peroxidation in cell membranes, leading to droplet
accumulation in glia a process that is exacerbated in neurodegeneration [112, 113].
Mitochondrial dysfunction has been linked to PD,
based on the discovery of the roles of PTEN-induced
putative kinase 1 (PINK1) and parkin (PRKN) in mediating mitochondrial mitophagy [114]. Mutations in PINK1
(PINK1) and PRKN (PARK2) genes were among the first
genes to be linked to autosomal recessive PD [115, 116],
and there has been increased focus on mitochondrial
roles of inherited gene mutations in PD [117]. For example, LRRK2 mutations lead to α-synuclein aggregates on
the mitochondrial outer membrane [118, 119]. It should
be noted that PD-associated genes PINK1 and LRRK2
are highly enriched in astrocytes over other CNS cells
[120, 121] – again implicating non-neuronal cells and
inflammation in the pathogenesis of this neurodegenerative disease.
Impaired energy metabolism and defects in expression of genes related to mitochondrial bioenergetics
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are commonly associated with characteristics of AD
pathology [122], including altered mitochondrial biogenesis, mitophagy, fusion/fission and axonal transport of mitochondria [122]. For example, Aβ aggregates
cause increased ROS production that can activate
downstream proteases that act on mitochondrial fission/fusion GTPases [122]. In the case of mitochondrial transport, Aβ associates with motor machinery
including kinesins [123] and dyneins [124]. In glaucoma, evidence of mitochondrial dysfunction is commonly associated with RGC degeneration. Abnormal
mitochondrial morphology and distribution has been
noted in humans and animal models [125, 126]. In a
model of murine glaucoma, mitochondrial transport
in RGCs (including number of transported mitochondria, distance transported, and rate of transport) is
affected both in the early and late stages of the disease
[127]. Furthermore, aged mice exhibit differences in
mitochondrial transport and are more susceptible to
elevated IOP-driven changes than young mice [127].
Elevated IOP also affects mitochondrial bioenergetics
in the visual cortex of the brain in rats; ATP production was reduced, superoxide production was increased
and differential mitochondrial complex activity was
observed [128].
More generally in neurodegenerative conditions,
mitochondrial transport might be hijacked to communicate a stress signal after a local lesion or infarct.
Conversely, the movement of mitochondria could be
harnessed therapeutically for viral delivery or to promote increased clearance of waste products in disease. When mitochondrial dynamics are altered, either
through dysfunction or genetic mutation, the impact
for neurons can be catastrophic. The retina is one of the
most metabolically active tissues and requires precise
regulation of energy supply to meet demands [129]. The
unmyelinated portion of the RGC axon in the retina
lacks saltatory conduction and therefore is less efficient
generating action potentials [107]. Since RGCs rely
heavily on mitochondria in the unmyelinated segment,
dysfunctional mitochondria lead to optic neuropathies
that result in vision loss. Many of these optic neuropathies occur through the inheritance of a specific genetic
mutation. For example, mutations in Optineurin
(OPTN) affect mitophagy and these have been linked
to incidence of glaucoma [130]. Mutations in the OPA1
gene affect mitochondrial fusion and leads to dominant
optic neuropathy, the most common inherited optic
neuropathy [131]. Mitochondrial DNA (mtDNA) can
also harbor mutations that lead to disease, including
Leber’s Hereditary Optic Neuropathy (LHON), which
can occur due to a mutation in any of several mtDNA
genes [132, 133].
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Neurovascular coupling

The metabolic demands of the CNS necessitate a tightly
controlled supply of nutrients and metabolites to maintain cellular homeostasis. Neuronal activity (i.e., metabolic demand) and blood flow (i.e., metabolic supply) are
coupled such that an increase in neuronal activity evokes
increased blood flow to the area [134]. This neurovascular coupling is mediated by multiple cell types that
together comprise the neurovascular unit (NVU) [135],
including vascular smooth muscle cells, pericytes and
endothelial cells as well as astrocytes, microglia and oligodendrocytes [136–139]. Aside from metabolic support
and waste removal, a major role of the NVU is to maintain the integrity of the blood-brain-barrier (BBB), which
mediates controlled communication between the CNS
and the periphery [140, 141]. The BBB protects the CNS
from the systemic circulation and regulates the transport
of serum factors and neurotoxins, which could perturb
homeostasis [142]. The BBB is not passive; the presence
of specialized tight junctions and transporters on luminal
and abluminal membranes along with membrane-bound
enzymes make it a highly selective and metabolic site of
exchange [143]. A specialized CNS glymphatic system
involving cerebral spinal fluid, interstitial fluid and lymphatic vessels contributes to the exchange of nutrients
and signalling molecules with clearance products such
as proteins and solutes in the brain parenchyma [141].
Recently, an ocular glymphatic system was described as
an eye-to-cerebrospinal fluid (CSF) pathway that supports clearance of waste products from the retina and the
vitreous [144].
The function of the BBB and glymphatic systems of
the brain and ocular tissues are fundamental to neuronal
health and have implications in the progression of neurodegenerative diseases. Some 30% of dementia patients
are specified as suffering from VCID, which represents
the second most common cause of dementia after AD
[145, 146]. VCID arises from stroke or other vascular
injuries that cause significant changes to cognitive functions. VCID shares comorbidity with other common
dementias such as AD. Around 60% of AD patients show
significant signs of VCID [145], and VCID may involve
impaired clearing of Aβ, which is also observed in AD
patients [147]. Neurodegeneration also involves a compromise or breakdown of the NVU, which can arise from
the disruption of astrocyte connections with blood vessels [145]. Increased reactivity of astrocytes and microglia leads to changes in morphology that can destabilize
the NVU and compromise the BBB, which initiates of a
pro-inflammatory and pro-degenerative cycle involving
peripheral immune system invasion.
A risk factor for AD, APOE may be protective of the
peripheral vascular system, along with other molecules
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such as high-density lipoprotein (HDL). There appears to
be a functional interplay between lipoproteins and how
they modulate the vascular system, and in turn their indirect effect on neurons in the CNS. APOE peripherally
associates with HDL and has been linked to clearance of
Aβ in vitro [148]. While HDL and APOE work together
to help transport beta-amyloid into vessels, the ApoE2
isoform is more effective than other forms of APOE
[148]. Thus, HDL could be neuroprotective target in
amyloid-driven disease, as could APOE in the clearance
of α-synuclein in PD.
In glaucoma, although a vascular theory of the disease
has generated some debate over the decades [149–152],
the role of cells in the neurovascular unit in the disease
is only recently becoming clear [32, 153]. Glaucoma
involves alterations in the vasculature, both morphological (i.e. blood vessel diameter, capillary dropout) and
functional (i.e., NVC dysfunction) [32]. Neurovascular coupling in the ONH and retina has been elegantly
demonstrated through measurements of hemodynamic
responses to flicker-light stimulation [154–157]. In glaucoma patients, flicker-light induced retinal vasodilation
is diminished [158, 159]. Interestingly, short-term acute
IOP elevations do not alter flicker-light responses, suggesting diminished responses in glaucoma are not due to
changes in IOP alone [155]. This evidence hints at underlying dysfunction in the NVU, either due to reduced neuronal activity or altered glial cell function [160, 161].
Recently, an important role for pericytes in coordinating NVU responses in the retina has been highlighted as
an integral component of RGC homeostasis and function
[153]. Pericytes are highly mobile and interact to finely
tune blood flow through capillaries in the retina through
inter-pericyte tunnelling nanotubes (IP-TNTs), as visualized though in vivo imaging [153]. Pericyte IP-TNTS are
a key component of microcapillary blood flow regulation
and are damaged in ocular hypertension [162]. This work
highlights not only a potential role for dysfunctional pericyte networks in neurodegeneration, but also the accessibility of the retina as a model for CNS disease. In addition
to neurodegeneration of the retina, a pathogenic role for
APOE4 in pericytes has also been shown in an in vitro
model of cerebral amyloid angiography, reiterating the
important role of pericyte function in neurodegenerative
disease [163]. Understanding how pericytes react in retinal disease could inform mechanisms of neurodegeneration in AD, PD and traumatic brain injury.
Genetic contributors

Characterization of genes responsible for neurodegenerative diseases allows at least partial understanding of
risk through inheritance of disease-associated alleles,
and thus heritability is often used as a population-based
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measure of risk for developing a particular disease. Heritability is formally defined as the proportion of phenotypic variance due to genetic factors, although it does not
mean that inheritance of a gene will cause disease, and
similarly not all individuals with the disease will carry the
same risk alleles. Progressing from heritability to disease
mechanisms is not a trivial task. One important question to consider is whether the risk allele resides in a gene
directly affecting disease, e.g., is it monogenic in nature
(a “core gene”), or whether it is a mutation in a “peripheral gene” only indirectly affecting the course of disease
through potential regulation of or interaction with core
genes [164]. Although genome-wide association studies
(GWAS) have identified novel single nucleotide polymorphisms (SNPs), these have generally not been useful for
generating disease risk predictive models for use in the
clinic [165]. One major reason for this is that many neurodegenerative diseases are polygenic in nature [166]. A
better determination of genetic risk of developing disease is through the compilation of a polygenic risk score
(PRS). The score considers the small effects of many
genetic variations that contribute to disease risk, better
capturing the polygenicity of a disease. Indeed, capturing
the polygenicity of a disease may lead to the identification
of co-morbidities between diseases and common mechanisms to combat more generally a broad range of neurodegenerative diseases.
Genome-wide association studies have been critical
for identifying risk factors in AD [164] and studies have
highlighted common gene-linked pathways e.g. APOE4
and the closely associated lipoprotein CLU [167]. As
noted above, APOE4 is a shared risk factor for both AD
and Parkinson’s disease dementia (PDD), and there is evidence for an APOE-genotype effect on multiple aspects
of protein aggregation, inflammation, and neurodegeneration across several distinct diseases including AD
and PDD [168–171]. Studies that have combined genetic
risk factors across diseases in mice have provided an
insight into the mechanisms linking APOE genotype to
other neurodegenerative disorders. Transgenic mice that
develop alpha-synuclein pathology (Lewy bodies) have
been genetically crossed to genetic isoforms of the APOE
gene [172, 173]. APOE2 genotype protects against alpha
synuclein degeneration compared with other APOE genotypes while APOE4 genetic background had the highest
burden of alpha synuclein pathology [172]. These results
raise the questions of whether the effects of the protective APOE genotype are executed at the gene level or at
the level of protein, which has ramifications for leveraging genetics to create neuroprotective gene replacements.
Like many genes that putatively harbor disease-associated mutations APOE is enriched in astrocytes and
microglia.
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The effect of sex differences on neurodegeneration is
intriguing and highly complex. In the CNS, sex differences are generated by both long- and short-term epigenetic changes caused by gonadal hormones and their
interaction with transcriptional gene products found
on sex chromosomes [174, 175]. Sex hormones and sex
chromosomes therefore each play a part in the response
of the CNS to diseases and aging [174]. Aging and disease
are both associated with changes in levels of hormones,
such as testosterone, estradiol, progesterone, and downstream neuroactive metabolites [176]. Primary examples
of changes in levels of hormones are in pregnancy or during menopause with both affecting the process of brain
aging in females [177].
Of the studies that have focused on sex differences in
neurodegenerative disease, many have highlighted a clear
role of differences between male and female biology in
disease progression. In these studies APOE4 increases
the risk of AD to a greater degree in women than in men
[178], women are less likely to recover from stroke than
men [179], estrogen has proven neuroprotective effects in
females [180, 181], and sex differences exist in the use of
cholinesterase inhibitors for the treatment of AD [182].
Interestingly, sex-driven pathophysiological changes in
neurodegenerative disease have also been linked to glial
cell populations [174]. Indeed, the sex chromosome
complement determines differences in transcriptional
responses in glia in response to injury or disease [174].
Furthermore, downstream metabolites of gonadal hormones can interact directly with hormone receptors on
many types of glial cells to elicit specific neuroprotective
responses [174, 183]. As well as possible direct effects
of sex hormones on neuronal health, sex hormones can
also affect the vasculature which indirectly affects neuronal survival. The role of sex hormones in maintaining the integrity of the BBB has been recently reviewed
[184]. Moreover, the vasculature in the can generate sex
hormones locally [185]. Sexual dimorphisms are also
abundant in glaucoma; there is increasing evidence that
lifetime exposure to estrogen may alter the pathogenesis
of glaucoma and that estrogen may have a neuroprotective effect on progression of POAG [186, 187].
Over the last decade, genetic studies including GWAS
have identified over 260 risk alleles for glaucoma. Studies
of heritability of disease have shown that glaucoma, specifically POAG, is one of the most commonly inherited
diseases [188]. Family-based linkage analyses have identified three monogenic risk genes for the disease: MYOC,
TBK1 and OPTN [188]. Monogenic risk factors, however, only account for less than 5% of all cases of POAG,
suggesting that risk factors for the disease are polygenic
in nature; high heritability is due to hundreds or maybe
even thousands of gene variants with an additive effect
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on disease inheritance. Many of the risk factors that have
been identified are still related to IOP, thus there is a
need for larger patient cohorts to identify additional risk
alleles for the disease [189]. The polygenic nature of the
disease makes discovery of single-gene loci less impactful. To date, there has not been a monogenic-based gene
therapy for glaucoma in clinical trials. Numerous possible applications of gene therapy targets include increased
aqueous humor drainage for long-term IOP stabilization,
inhibition of fibrosis following filtration surgery, modification of scleral biomechanics for IOP tolerance, RGC
neuroprotection and neuro-regeneration, and inhibition
of inflammation [190, 191].
In a very recent, high-powered PRS study using glaucoma patient data from United Kingdom, Australia and
the United States, the investigators were able to predict glaucoma susceptibility and progression [166, 192].
Using the PRS enabled the detection of patients in the
early stage of disease who were particularly high-risk
and detection of lower risk patients who could undergo
a less-intensive monitoring strategy. The PRS strategy
for glaucoma is pioneering in its approach to identify
patients who may benefit from potential neuroprotective
treatment and represents the first step towards personalized medicine decision-making for glaucoma.
Detecting and tracking neurodegeneration

Once triggered, symptoms of neurodegeneration may not
be apparent until late in progression. Providing patients
with a neuroprotective treatment prodromally or early
in disease requires definitive early biomarkers, a prospect limited by our understanding of molecular events
in disease progression, the pleiotropic nature of most
degenerative diseases, and the ability to detect putative
biomarkers with sufficient sensitivity. As well, there is
a certain level of heterogeneity in clinical presentation
from patient to patient. For example, in glaucoma, measurable outcomes such as minor visual field deficits, optic
cupping and IOP readings in early disease can be easily
missed and are highly variable and perhaps less reliable
[193, 194].
Although genetic risk factors can inform clinicians of
high-risk patients, carrying a disease allele does not necessarily imply disease. Identifying shared biomarkers
early in progression across a range of neurodegenerative diseases will enable very early detection of changes
at the molecular level before neurodegeneration occurs,
providing a larger window for therapeutic intervention.
The term biomarker has been defined by the National
Institutes of Health as “a characteristic that is objectively
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [195]. The
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objective of identifying new biomarkers for clinical and
therapeutic research is to provide a readable output that
is robust, reproducible and reliably able to report on clinical outcomes in disease, i.e. is able to provide a reliable
prediction of disease onset, progression, prognosis or
outcome after therapeutic intervention [195]. The identification of subgroups of patients with specific biomarkers
may lead to the identification of the most effective therapies [196]. Furthermore, biomarker-targeted therapies
may be more efficacious at different time points in disease. Early biomarkers for disease detection are therefore
urgently needed.
Biomarkers for disease

Progress in the detection of early neurodegenerative disease biomarkers in biological fluids, such as CSF, saliva,
and blood has advanced dramatically. These advances
have been reviewed in detail recently [196, 197]. Potential
fluid biomarkers that fall under the main pathophysiological aspects of neurodegeneration including blood tests,
protein aggregates, neuroinflammation markers, and cell
death markers have been characterized for many diseases
[197]. Primary targets for detection include biomarkers
of Aβ pathology, tau pathology, α-synuclein pathology,
proteins associated with neurodegeneration, and markers of glial reactivity, for example GFAP [196] (Fig. 2). In
addition to fluid biomarkers, high-powered neurological imaging has proved to be a potentially powerful tool
for detecting early manifestations of neurodegenerative
disease. Imaging modalities currently include magnetic
resonance imaging (MRI) and positron emission topography (PET) analysis [198]. Novel PET ligand portfolios
for specific neurodegenerative diseases, combined with
structural analysis using MRI have enabled the further
understanding of temporal changes in neuronal tissue
in degenerative neurological disorders. However, there
is an absence of cell sub-state specific imaging ligands to
offer high fidelity imaging to track disease progression or
effectiveness of therapies non-invasively in patients.
In CSF or plasma, the ratio of Aβ42/ Aβ40 reflects
Aβ pathology in the brain of AD patients; the levels of
CSF Aβ42, but not Aβ40 decrease by up to 50% in AD
patients [199]. The detection of changes in CSF fluid Aβ
levels are found earlier than PET-detection in the brain
but correlate well with PET results [199, 200]. Indeed,
a recent publication with head-to-head comparison of
eight plasma amyloid-β 42/40 assays in AD showed that
the PrecivityAD™ CLIA-approved mass-spectrometrybased blood test performed better when predicting brain
pathology [201]. Tau pathology is another protein readily
measured in AD patients through PET imaging or fluid
analysis. Several PET ligands, specific only for insoluble
Tau fibrils in AD brain tissue have been implemented in
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Fig. 2 Biomarkers for neurodegenerative diseases. Numerous biomarkers for neurodegeneration are being developed. Amyloid pathology in AD
can be readily detected in plasma by measuring the Aβ42/ Aβ40 ratio. Alternatively, larger Aβ plaques and fibrils can be detected visually by Aβ-PET.
Similarly, tau pathology can be detected as p-tau in plasma and cerebrospinal fluid (CSF), and tau plaques can be identified as fibrils on PET. Lewy
bodies, composed of misfolded α-synuclein (α-syn), can be detected in CSF of PD patients or by using α-syn seeding assays such as α-syn RT-QuIC.
Neurofilament light protein (NfL), a marker of degenerating myelinated axons is detectable in CSF and plasma. Several novel emerging biomarkers
include neurogranin, a marker of post-synaptic degeneration and synaptic vesicle 2 A (SV2A), a pre-synaptic marker of degeneration. In addition,
the presence of reactive gial cell markers (e.g., glial acidic fibrillary protein; GFAP, monocyte chemoattractant protein-1; (MCP-1) and Triggering
Receptor Expressed On Myeloid Cells 2; TREM2) in CSF and plasma are being explored as novel biomarkers in neurodegeneration

AD diagnostics [202, 203]. Other markers of neurodegeneration include Tau post-translational modification
markers [204], which are suggestive of myelinated axon
degeneration. In PD, misfolded α-synuclein is reliably
detected in CSF, with levels decreased in PD patients
[196]. Other methods for sensitive detection of misfolded
prion-like proteins have been implemented including
cell-free seeding assays (e.g., α-syn-QuIC) [196]. Seeding assays use CSF samples to detect pathological aggregations of protein and preliminary experiments indicate
that the technology could be done using non-invasive
skin biopsies [205, 206].
To detect widespread neurodegeneration in the brain,
structural magnetic resonance imaging (MRI) is used.
MRI allows accurate determination of temporal changes
in gray and white matter volumes and such studies have
been carried out longitudinally in clinical trials [207].
One drawback to MRI is that it does not allow the detection of specific cell populations that may be particularly

vulnerable to neurodegeneration. High-resolution protein-specific methods, such as PET, have correlated
changes in specific synaptic proteins, such as synaptic
vesicle 2 A (SV2A), with AD and PD onset and progression [208, 209]. Additional fluid detection of markers
associated with neurodegeneration include neurofilament light protein (NfL) [210], which shows the presence of brain injury in a number of neurodegenerative
diseases, autophagosomal and lysosomal markers as
indicators of cell degeneration [211], and neurogranin,
a marker of post-synaptic degeneration [196]. Neuroinflammation is a common mechanism across neurodegenerative diseases and there is an increased interest in
examining neuroinflammatory markers as indicators of
early disease detection and progression. For example, the
presence of active glial cell markers such as GFAP, monocyte chemoattractant protein-1 (MCP-1), and sTREM2 in
CSF [211, 212]. In multiple sclerosis patients, increased
levels of CSF GFAP have been found to correlate with
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disease severity and progression [213]. In early stages of
AD, increased levels of sTREM2 in CSF are detected in
patients [212], whereas in late stages of the disease there
are increased levels of MCP-1 [212]. Novel markers of
cellular degeneration and neuroinflammation may enable
clinicians to identify sub-populations of patients at early
or late stages of disease for novel therapeutic treatments.
Imaging in glaucoma and beyond

The retina, as an extension of the CNS, provides a noninvasive and easily accessible window for high-resolution
imaging of CNS tissue. In glaucoma, light-based imaging modalities such as fundoscopy and optical coherence
topography (OCT) are more accessible and cost-effective
than neural imaging to assess neurodegeneration. RGC
degeneration in glaucoma is routinely visualized in the
clinic using OCT and presents as thinning of the retinal
nerve fiber layer [214]. Retinal vasculature can also be
readily visualized using OCT-angiography (OCT-A) and
fluorescein angiography and provides the ability to detect
microvascular changes early in glaucoma progression.
Recent advancements in imaging technology in the eye
in conjunction with fluorescent annexin A5 has enabled
scientists to detect degenerating RGCs by DARC (Detection of Apoptosing Retinal Cells) in mice and in humans
[215]. DARC has moved into clinical trials with patients
and is a method well-tolerated, although DARC is currently used as an exploratory endpoint in disease [216].
Although future methods like DARC may aid in detecting populations of patients that have a rapid rate of disease progression, earlier visual biomarkers for glaucoma
are critically needed to detect disease before apoptosis of
RGCs is triggered.
Imaging of the retina for biomarkers is not exclusive to
diseases of the visual system such as glaucoma. In fact,
biomarkers for neurodegenerative diseases that primarily affect the brain have also been detected in the neural retina [217]. There are two plausible mechanisms by
which neurodegenerative markers may be present in
retinal tissue as well as in the brain. The first possibility
is that manifestations of neurodegenerative disease in
the brain are also concurrently appearing in the retinal
tissue. In the aging retina, deposition of aggregated tau,
α-synuclein and Aβ are detected [218]. In AD and PD
patients the same aggregations are also observed in the
retina [219, 220] which suggests that the protein aggregations may mediate neurotoxicity to RGCs in the same
manner as neurons elsewhere in the CNS. The second
mechanism may occur due to alterations in the brain
with neurodegenerative pathology that cause retrograde
degeneration of RGCs [217, 221]. In AD, in vivo studies
using OCT have found reduced retinal layer thickness
[222–225], and reduced microvascular density [226, 227].
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Detection of early biomarkers for other neurodegenerative diseases in the eye raises the possibility that the
eye could be used as a window to the CNS to monitor
biomarkers for neurodegenerative disease in general.
There are many benefits to visualization of biomarkers
in the eye. Firstly, the process can be minimally invasive
and easily accessible. The ability to quantify meaningful molecular biomarkers streamlines patient cohorts
for putative clinical trials, reducing noise and enabling
smaller, more powered clinical trials [197]. However, systems to visualize pathologies in the eye are limited not
only by technological limitations and generating high
resolution images, but also by the analysis of such images
and lack current understanding about the pathophysiological role of the biomarkers being targeted.
Model systems for testing therapeutics

The ability to accurately and robustly mimic human disease in the laboratory is key to the success of developing
therapies that will translate well into the clinic. However,
numerous recent failures in the translation of pre-clinical
therapeutics from the bench to beside in clinical trials
have raised doubts about the relevance of current animal
models for human diseases Current in vitro, ex vivo and
in vivo model systems are illustrated in Fig. 3. The etiology of neurodegeneration in human diseases is highly
complex, involving multiple cell types, cellular signaling
pathways, genetic loci, and environmental cues. Attempts
to encapsulate all aspects of a human disease with a single model have not been fruitful. As insights into human
diseases grow, translatability of experimental models is
an important consideration for the design of novel therapies. For example, mouse models of AD which have been
broadly based on human genetic studies, accumulate
Aβ but do not develop other common pathologies such
as neurofibrillary tangles [228]. Aβ therapy, primarily designed to inhibit Aβ production, aggregation or
enhance Aβ clearance, was largely successful in mouse
models of AD but did not translate in human clinical trials [229, 230].
Failure in translation of mouse models to humans
drives home the point that mouse models may not be
ideal for the development and design of human therapeutics. In many cases, the focus of therapeutic intervention is on neuronal populations, while other cell types
are not always considered. In AD, the role of vascular
dysfunction and immune reactivity are widely accepted
as reflecting the importance of cell types besides neurons
[231]. One of the possible reasons that genetic models
of AD do not translate to humans is that, while leading to the degeneration of neurons, they lack the robust
glial and inflammatory responses seen in patients [231].
An obvious bridge between rodent models and humans
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Fig. 3 Model systems for studying neurodegeneration. Established experimental models of disease can be categorized into three main
areas: in vitro, ex vivo and in vivo. Each type of model system has advantages that can be leveraged to explore disease mechanisms; however,
disadvantages exist for each avenue. In vitro models such as cell lines and purified primary cells are a rapid and inexpensive way to explore disease
mechanisms, however, extrapolation of results to biological systems is difficult. Ex vivo models, such as the growth of organoids in culture or
explanted tissue cultures are multicellular, allow more complex mechanistic questions to be explored. However, they are not ideal representations
of in vivo situations due to lack of vascular or peripheral immune components. In vivo models include animals such as non-human primates, mice
and rats, Drosophila and Caenorhabditis elegans, and others. Although these models allow for in vivo studies of disease, the cost is high, and the
results may not always translate well to human biology.

are non-human primates, although, the use of nonhuman primates comes with additional ethical issues and
extremely high costs. Since costs to house and maintain
non-human primates are so high, the number of animals
used in pre-clinical studies is often low, and perhaps
some would argue under-powered.
In glaucoma, inducible models are sometimes used to
the extreme [232, 233]. Some models in rodents reach
IOP elevations that are not physiologically relevant to the
human disease, with acute IOP levels increasing by up to
200–400% [234]. In fact, many patients with glaucoma
never present with elevated IOP, and it is clear that other
pathological mechanisms are at play. The optic nerve
crush model in rodents has developed into a useful tool
to study regeneration of RGC axons after injury, enabling
a greater understanding of the cellular and molecular
mechanisms that drive axon regeneration and RGC survival [235]. Such animal models of optic nerve injury have

determined that both cell-intrinsic and extrinsic (i.e.,
environmental) factors have distinct roles in the potential for RGCs to regenerate. Optic nerve crush studies are
also integral to identifying factors that may not be regenerative in nature, but rather are pro-survival in nature.
Pro-survival factors may also be key to enabling degenerating RGCs to remain viable long enough to move to a
pro-regenerative state.
In vitro systems of neurodegeneration

In vitro model systems offer a less expensive, highly
adaptable, and augmentable system for the highthroughput investigation of novel mechanisms in disease and the design of therapeutic interventions (Fig. 3).
In vitro model systems have grown exponentially in their
complexity in recent years. Initially, the use of primary
cell cultures and organotypic cultures provided researchers with a means to explore disease mechanisms [228].
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An attractive ex vivo model is the use of organotypic cultures of brain slices, whole neural retina or retinal slices.
Explanted tissue can be prepared from multiple animals
and in some cases human donor tissue and can faithfully
represent tissue architecture and cellular structure. Even
so, the ability to maintain viability in culture remains
notoriously challenging [236]. In the context of glaucoma, with what we now know about pathophysiology at
the optic nerve head and the need to produce axons that
span the length of the optic nerve, organotypic cultures
of whole optic nerve and whole retina would be most
relevant but are extremely difficult to isolate and maintain. In addition, organotypic cultures do not provide
long enough timeframes for the investigation of disease
processes that may occur more slowly, such as chronic
inflammation and neovascularization. An ongoing problem in many primary cell culture experiments is the
inclusion of serum in media. Serum is largely excluded
from the CNS by the BBB, and inclusion in culture
experiments irreversibly alters the gene expression profiles and functions of many glia and immune responsive
cells like astrocytes [237] and microglia [238, 239]. Similar artifacts can also be induced by the use of enzymes
in the digestion of CNS tissue when isolating microglia
[240, 241]. Updated methods exist to grow these cells in
serum-free defined media [237–239, 242], but they have
not been widely applied for unknown reasons. The use of
mixed-species multicellular co-cultures has also helped
to remove many of the artifacts of serum culture [243].
Human-derived induced-pluripotent stem cells (hiPSCs) from human donors have been useful for generating multiple cell types harboring the same genetic
background [228]. This has been particularly important
for the study of patient genetics in disease; neurons and
other cell types carrying disease-specific genetic mutations can be assessed longitudinally in culture. In early
experiments, 2D cell cultures failed to recapitulate cellcell interactions, and the introduction of scaffolding
materials such as agarose and hydrogels has promoted
3D tissue-like structure that better models disease [228].
These innovative reconstructions of CNS tissues may be
advantageous when it comes to understanding disease
progression.
Organoid cultures

Growth and differentiation of hiPSCs in culture has
led to cerebral organoid structures that can exist for
several months and exhibit similar manifestations of
neurodegenerative disease as the human donors from
which they were obtained [244, 245] (Fig. 3). Such
studies provide the ability to assess the impact of disease genes on physiological processes over time, highlighting key windows of opportunity in the disease
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progression [246]. In addition to brain, human retinal organoids have been developed with mature photoreceptors that have the ability to respond to light,
bringing retinal organoids one step closer to being successfully used for disease modelling, and perhaps even
for the regeneration of the retina in patients that have
lost vision [247].
A potential problem in the generation of organoid
structures, however, is the variability of cell types
within cell populations produced when culturing hiPSCs. To better interpret results from organoid cultures,
improvement in single-cell characterization is needed.
Novel quantitative platforms have recently been developed that may help overcome this issue. These systems
have the capacity to analyze human organoids at a single cell level on a large scale to improve quality and
reproducibility of organoid structures [248].
One drawback to organoids is the lack of vascular elements, and thus efforts to develop in vitro
neuronal-vascular systems are becoming increasingly important as organoid cultures become more
complex. Combining in vitro vascular models with
multifaceted cellular neuronal circuitry will be pivotal. Also, the BBB and BRB are fundamental to the
maintenance of neuronal health and homeostasis in
the CNS and are also implicated in neurodegenerative pathology. However, incorporation of vascular
elements into in vitro model systems is not simple.
In fact, regenerating the multicellular organization
of the neurovascular unit is itself a challenge. A very
recent study has made a huge step forwards in modelling the neurovascular unit in conjunction with
neurons in vitro [249]. The model system utilizes a
scaffold-directed approach and multiple cell types,
including induced pluripotent stem cell-derived neurons, endothelial cells, astrocytes and smooth muscle cells to generate an in vitro model of an arterial
neurovascular unit [249]. Development of this system
will increase our understanding of the vasculature
in physiological and pathophysiological conditions
and may also provide a useful tool in the assessment
of novel drug therapies and drug delivery across the
BBB to promote neuronal survival. Another drawback
to the implementation of organoids in evaluating
mechanistic and therapeutic strategies for neurodegeneration is their lack of interaction with the PNS.
Infiltration of circulating PNS immune cells is often
associated with neurodegenerative disease progression, and organoid cultures do not yet address this
potential confound. Alternative strategies such as the
implantation of human iPSC-derived organoids into
the rat brain to enable vascularization have proven a
novel way to potentially overcome this problem [250].
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A look ahead: new model systems

The advantages of in vitro model systems are twofold for
designing new treatments. Patient-derived hiPSC human
organoids can be cultivated and analyzed over time so
that the disease phenotype of the tissue can potentially be
fully characterized over time. This opens the possibility of
being able to visualize key changes at various time points
in disease progression, and windows of opportunity for
novel therapies. Also, in vitro organoids provide a biological system to test promising therapeutic treatments in a
potentially more relevant model of disease than mice or
cell cultures alone. In view of the flaws in using mouse
models mentioned above, and with increased funding for
in vitro models, and ethical considerations explored and
defined, in vitro model systems could reduce the time
and money wasted in the failure of clinical trials by providing a more translatable pre-clinical model.
Human-derived in vitro models are advancing in their
complexity and so to overcome the limitations of mice
as model systems, mice with human neural transplants
can be generated. The brains of these mice are a combination of in vitro hiPSC-derived neural cells engrafted
into mouse models, opening up a possible alternative
approach to studying the role of specific cell types in disease [231]. Such mice balance the advantages of having
a living organism and the translatability of hiPSC-neural
cells in one model but raise the issue of ethics of crossspecies models. The current consensus is that these models are unlikely to have complex human characteristics,
but still raise issues regarding animal welfare that need to
be addressed [251].
Although technical challenges are evident in the generation of novel model systems, it is also important to
consider the ethical limitations, safety, and interpretation
of these exciting new avenues of research. The successful
generation of hiPSC-derived organoids raises an exhaustive list of ethical concerns, including informed consent
and privacy of cell donors, the potential for organoids
to develop human characteristics or qualities, the use of
transplantation or even gene editing [252]. The importance of this topic is paramount in the future use of organoids, neural transplants or chimeric model systems for
neurodegenerative research [251, 252].
The evolution of human-like organoids and 3D cell culture systems could revolutionize the approach to drug
discovery and development, saving money and time and
enhancing translatability to human clinical trials. At present, procuring funding for the development of in vitro
systems is arguably more challenging than most other
model systems, such as mice. One issue is that in vitro
model systems are not widely used or easily validated.
With increasing studies and improved technologies and
ethical considerations, in vitro systems such as hiPSC
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organoids to model healthy and diseased conditions will
facilitate a new era of personalized and precision medical
treatment.
Opportunities for new therapeutics

Across all studies in neurodegenerative disease, a fundamental theme in designing therapies and, ultimately,
a cure, is finding the right intervention at the right time.
Neurodegeneration is progressive and enhancing our
understanding of the temporal aspects of neurodegeneration will inform check points for neuroprotection and
regeneration. Neuroprotection relies on the understanding of key molecular changes in tissue as it moves from
homeostatic (i.e., healthy) to diseased. The goal for neuroprotective treatment is to provide tissue with the necessary factors to support healthy neurons and to prevent
neurodegenerative changes at the molecular level from
occurring. A major benefit to providing patients with
neuroprotective intervention is that it has the potential
to stop the degeneration of otherwise healthy neurons,
without the trauma of developing symptoms associated
with neuronal death such as cognitive decline in the
brain and loss of vision or the challenge of replacing lost
cells in the retina.
Patients with increasing cognitive decline due to AD or
other neurodegenerations of the brain are patiently awaiting disease-modifying therapies, or therapies that could
restore the loss of functional neurons. In addition to people living with end-stage AD-related dementia, a subset
of individuals exhibiting pre-symptomatic pathology may
benefit from interventional neuroprotective treatment
[253]. In line with other areas of the adult mammalian
central nervous system, the optic nerve does not have
the ability to repair itself after injury. For patients who
have lost their vision, restoration may involve complete
replacement of lost cells and regeneration of optic nerve
axons, or axon-regeneration and rejuvenation of surviving but compromised RGCs [254]. Here we outline the
key areas that are providing researchers with the hope
to restore cognitive function in patients with neurodegenerative brain diseases or restore vision in glaucoma
patients.
Leveraging genetics for neuroprotection

With increased understanding of the genetics of neurodegenerative disease comes the opportunity to leverage genetics to inform new treatments. There are two
main ways that genetics can be leveraged: (1) through
therapy targeted to a causative allele, and (2) by countering the downstream effect of a disease gene pharmacologically. One common disease-associated gene in AD
is the microglial gene TREM2; gene variants in TREM2
increase the probability of developing AD by around
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2-3-fold [255–257]. Microglia are central to multiple disease pathologies as discussed (i.e., BBB integrity, clearage
of waste and Aβ plaques, altering synaptic relationships,
reactivity of other glia), and hyper-reactivity of microglia is linked to pathogenesis in neurodegenerative disease. However, human genetics tells the opposite story
– all mutations in TREM2 lead to decreased functionality
[258]. By application of genetics, there is the potential to
shift cells, such as microglia, to a pre-degenerative state,
potentially rendering them neuroprotective.
Many traits in neurodegenerative disease are genetically correlated in a phenomenon known as pleiotropy,
whereby a genetic locus affects multiple characteristics
[259]. Identifying potential genetic crosstalk between
genes in neurodegenerative pathology has the potential
to serve as a therapeutic target for treatments that simultaneously prevent or treat multiple diseases. Identifying
high-risk genetic alleles makes possible the road to gene
therapy by silencing or replacing disease-causing genes
with non-mutant forms. Gene-based diagnostics and
screening also enables the identification of individuals
at risk for a particular disease before irreversible damage occurs. Identifying patients based on genetic screening can also refine patient cohorts for clinical trials, for
example using genetics to define inclusion conditions for
a novel drug therapy.
Genetic analysis of neurodegenerative disease can also
give rise to potential downstream drug therapeutics.
There is an association of more than a hundred loss-offunction mutations in Progranulin (PGRN) that cause
early-onset dementia [260]. Progranulin is an immune
regulatory protein with neurotrophic properties but
decreasing the level of PGRN leads to hyperactive microglia and over-secretion of inflammatory mediators, which
leads to neurodegeneration. A potential therapy may
therefore involve preventing the breakdown of PGRN
with drugs targeted specifically to the protein. In this
way, genetics has informed us of alternative down-stream
pathways that can be targeted in the disease.
The multifactorial nature of AD has been recently highlighted by the development of a multiplex model [261].
AD encompasses genetic mutations in genes across many
functionally-distinct molecular pathways; over 50 genetic
loci have currently been identified in the development
and progression of the disease [261]. This has spurred
on the generation of several AD-related mouse models
and cell lines, although many of these models focus on
single gene effects [261]. Genetic studies have changed
our understanding of AD and other related dementias
and exploring neuroprotective therapies in the future
will rely on assessing multiple gene outcomes in disease
models. The challenge of modeling polygenic diseases in
animal or cell models is a hurdle that urgently needs to
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be addressed to create a better understanding of disease
mechanisms and to provide treatments that translate well
in the clinic.
Since multiple disease pathologies are commonly associated with neurodegeneration, multifactorial disease
therapies may prove more effective than monotherapies targeting one aspect of the disease [262]. Combination therapies have been successfully implemented
in the treatment of previously life-threatening diseases
such as cancer, tuberculosis and HIV/AIDs. Since AD
exhibits multiple co-occurring pathologies such as vascular brain injury, Lewy body pathology and TDP-43
inclusions [262], treatment to tackle these pathologies
together may show more promise than previous failed
attempts, such as clinical trials using anti-Aβ as a monotherapy. An example of such therapy might combine
anti-Aβ to promote immune-clearance of Aβ aggregates,
with an inhibitor of β-secretase, the enzyme responsible
for the production of toxic Aβ [262]. Similarly, glaucoma
shares co-morbidity with systemic vascular diseases
such as hypertension, and BRB breakdown has recently
been highlighted as an important, yet overlooked disease
mechanism [32]. Future neuroprotective treatments that
combine current IOP-lowering therapies with therapeutics to target novel aspects of pathology such as vasculartargeted drugs or immune-suppressing therapies may be
more efficacious than monotherapies in the clinic.
Before effective combined therapies can be offered,
however, we need to fully understand the interplay of
genetics and progression vs. initiation of disease. Understanding the genetic influence on disease risk will require
much larger patient cohorts with combined analyses
that includes GWAS, PRS and pathway analysis to better
inform studies that aim to identify common genetic risk
factors for neurodegenerative disease and leverage them
for treatment. In addition, identifying where temporally
in disease progression a particular gene exerts its effects
is lacking in most studies.
The promise of regeneration

With no current cure or effective treatment for neurodegenerative disease and patients progressing to cognitive
decline, blindness or even death, neuro-regeneration is
the only option to restore otherwise degenerated neurons. For neurodegenerative diseases that primarily impact the brain, such as AD and PD, neuronal loss
within cortical and subcortical regions of the brain can
be problematic to regenerate due to the potential invasiveness of the procedure required [263]. An ongoing
question in neurodegenerative disease is how the peripheral nervous system can regenerate after injury whereas
the central nervous system has a very limited capacity for self-renewal and repair. The unique ability of the
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peripheral nervous system to regenerate after injury has
been in part credited to resident Schwann cells [263].
Schwann cells are exclusively found in the peripheral
nervous system and have the capacity to drive neuronal
repair and axon regeneration after injury through dedifferentiation and reprogramming. Re-programmed
Schwann cells promote demyelination and secrete neurotrophic factors, growth factors, and other neuroprotective factors to support axon regeneration [263].
In the brain, utilizing elements of the peripheral nervous system, either through grafting or with purified
Schwann cells, has shown extraordinary potential in a
small number of non-human primate studies, and in
human trials in patients with PD, HD and in mice and
rats with spinal cord injury [263]. In trials to demonstrate
safety of these procedures, patients underwent autologous grafts of peripheral nerves into regions of the brain,
or transplants of purified Schwann cells without reports
of serious complications and mild improvements in cognitive function [263]. The studies were largely underpowered but do provide some insight into the cells and
environment needed to encourage axonal regrowth in
the central nervous system. In the central nervous system and by extension the visual system, Schwann cells
are absent, but oligodendrocytes fill the role of supporting neurons and myelination of axons. Although some
remyelination may occur spontaneously after injury
[264], oligodendrocytes generally lack the capacity for
regeneration. Oligodendrocyte precursor cells (OPCs)
present in the optic nerve, can undergo a transient period
of proliferation after injury, however, the response is not
sustained, and the cells fail to differentiate into myelination-competent oligodendrocytes [265]. Interestingly, the
augmentation of intrinsic OPC signaling through GPR17
coupled with microglial depletion promotes differentiation and the remyelination of regenerated axons, offering
a potential de novo strategy for remyelination after CNS
injury. With advances in stem cell-derived cell types, it
may prove feasible that stem cell-derived oligodendrocytes could promote repair and regeneration of the myelinated segments of the optic nerve after injury.
By characterizing the injury response of RGCs after
optic nerve crush, several intrinsic RGC-specific factors have emerged with regenerative potential, including deletion of PTEN and SOCS3 or manipulating a
variety of transcription factors. In addition, extrinsic
factors such as the mTOR-activating proteins such as
Osteopontin and several others growth factors have
been [254, 266]. By generating a triple deletion murine
mutant (PTEN−/−/SOCS3−/−/CMYC−/−) combined with
CNTF treatment, lengthy optic nerve axon regeneration after injury was achieved; similar effects have been
obtained by combining intraocular inflammation (to
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elevate Oncomodulin and SDF1) with cAMP elevation
and PTEN deletion [266] or by manipulating the mTOR
pathway while providing physiological stimulation [267].
Understanding the intrinsic and extrinsic factors that
promote outgrowth and survival of RGCs may place us
in a better position to coax a regenerative state.
The role of cell extrinsic factors, such as inflammation
are also important in regeneration. As in the peripheral
nervous system, triggering of an inflammatory response
and release of pro-inflammatory mediators can stimulate
regeneration of axons. In the eye, lens injury alone is sufficient to stimulate axon growth after crush [268, 269],
as are several other pro-inflammatory stimuli [100, 270].
Indeed, in ophthalmic surgery for glaucoma patients,
where laser stimulation in some treatments stimulates
repair, is it possible then that generating a small amount
of local inflammation could encourage reparative growth
in the optic nerve? Identifying factors crucial to regeneration of RGC axons is fundamental in generating
axons, however, the regenerated axons need to function
optimally as mature developed, healthy RGC axons. An
important consideration moving forwards in regenerative
research is understanding how promoting axon regrowth
affects RGC axon function; do factors that promote
regeneration also support RGC axon function?
Glia‑specific therapies for neurodegenerative disease

Multiple and parallel immune cell-astrocyte-neuron
signaling axes active during health and disease could
provide an exciting possibility for novel drug targeting.
What is quite exciting is the commonality of some of
these heterogeneous populations across diseases [104],
which may provide therapeutic avenues that need not
be disease specific. Preliminary investigation into therapeutic targeting of reactive astrocyte sub-states has been
leveraged in mouse models of PD where abatement of
immune cell dysfunction, and mitigation of astrocyteinduced neuron cell death appears possible using glucagon-like 1 peptide receptor agonists. Such drugs target
microglia to minimize astrocyte-reactivity inducing
cytokines [74]. This treatment is also reported to produce beneficial outcomes in the bead occlusion mouse
model of glaucoma [75]. Other possible therapeutic
angles include targeting astrocytes to enhance glutamate
re-uptake to minimize glutamate excitotoxicity that is
reported in ALS, HD, AD, and other diseases [45, 271,
272]. Other approaches would include global inflammation dampening, or block of specific detrimental reactive
astrocyte functions (e.g., production of toxic lipids); or
enhancement of other supportive functions like trophic
support, synapse formation, or other important developmental functions of astrocytes. For microglia, effective
targets would limit pro-inflammatory cytokine release
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[74] or block toxic metabolite release. This approach is
particularly important in patients with mutations that
drive additional neuron susceptibility, like the recently
reported Grn−/− susceptibility in mouse models of
fronto-temporal dementia [273]. The same effect could
be achieved by enhancing phagocytosis to aid removal
of toxic pathogenic proteins – like recent efforts to target TREM2. More holistically, interventions with dietary
changes could prove very effective. The recent discovery
of peripheral immune cell reprogramming and bacterial
load in the gut that in turn cause reactivity changes in
microglia and astrocytes, effectively gives an accessible
peripheral target for a known astrocyte-mediated neuron cell death pathway in the CNS [274]. Future effective therapies may need to target individual sub-states of
reactive microglia or astrocytes to stop the initiation of
disease, slow progression of degeneration, or reverse the
effects of chronic diseases.
Cell replacement strategies to restore vision

Aside from encouraging axon regrowth, there have been
some promising studies attempting to integrate retinal
cells into animal models of retinal degeneration. Most
studies have involved transplantation of either purified
photoreceptor cells, retinal pigmented epithelial cells or
stem cell-derived photoreceptors into sub-retinal spaces,
close in proximity to where the cells are needed to infiltrate [275, 276]. Incorporation of RGCs into the retina
is somewhat more challenging, in part due to the likely
need for intravitreal delivery and penetrance through
the inner limiting membrane [277]. To date, efforts in
animal models have been hindered by either lack of integration of replacement cells, or by the capacity of new
cells to regenerate axons capable of traversing the distance between the retina and appropriate target cells in
the brain.
To improve cell titers and increased likelihood of cell
integration into the retina, retinal organoid grafts grown
in culture have been implemented in animal models. It
was hoped that retinal grafts may increase cell density
at the site of integration in the retina leading to greater
cell incorporation, yet RGC axons struggled to cross the
inner limiting membrane, suggesting that additional factors and/or inner limiting membrane disruption may be
necessary to promote cell integration [278]. To improve
RGC cell replacement strategies, a large effort to study
the development of human-derived retinal organoids
in vitro is underway. One challenge to this approach is
that human stem cell-derived retinal organoids contain
only a small percentage of RGCs and they do not survive
long in culture. Learning about the molecules that control the steps through organoid development and manipulating these pathways to generate more RGCs that can

Page 18 of 29

survive long-term may prove useful in improving cell
incorporation in vivo. Studies on the co-culture of stem
cell-derived ganglion cells has shown that co-culture
with Müller glia or conditioned media improves survival
and axonal growth in culture, suggesting that addition of
these factors may help to encourage the transplantation
of RGCs [279].
Replacement of RGCs in the retina is not trivial and
emphasis on RGC cell type is important when we consider the replacement of functional RGCs in the retina.
Recent genetic profiling of RGCs in mice revealed 46
molecularly distinct cell types, which subserve different
functions in the visual pathway [280]. Identifying how
different RGC subtypes respond to injury at the molecular level may hold the key to harnessing pro-survival factors. In a study of murine models of optic nerve crush
injury [280, 281] and ocular hypertension, alpha-RGCs
appeared particularly resilient following injury compared
with other subtypes [282]. Genetic profiling of RGCs may
highlight specific genes that are correlated with resilience
and regeneration. Recently published atlases of retinal
ganglion cell types in humans provide a starting point for
such analyses [283]. Equally important is to understand
how distinct RGC types are generated during development, and single-cell transcriptomic analysis of retinal
development have begun to provide insight on this subject [284, 285]. Understanding which genes in development promote RGC differentiation might allow us to
harness similar pathways for disease.
Advances for alzheimer’s disease

Past treatments approved by the US Food and Drug
Administration (FDA) have focused on targeting the
symptoms of AD, improving cognitive or behavioral
functions but not necessarily affecting underlying progression of the disease [286, 287]. This year the FDA
carried out an accelerated approval process for the first
disease-modifying treatment from Biogen, Aduhelm
(aducanumab), an anti-Aβ therapy for the removal of Aβ
plaques [288, 289]. The decision by the FDA has been
met with scientific controversary [290]. Prior to the
FDA’s decision for accelerated approval, clinical trials
were halted due to claims of futility, and the data did not
meet the rigorous criteria for FDA approval. In the clinical trials that did proceed, over 50% of patients presented
with localized brain swelling or microhemorrhages [291,
292]. Despite scientific dispute regarding the efficacy of
Aduhelm, production and marketing of the drug will
continue in conjunction with a 9-year prospective study
requested by the FDA to confirm clinical benefit.
Recently, the concept of resilience to AD pathology
or downstream neurodegeneration following pathology have opened up a new avenue of research that may
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highlight novel targets for disease intervention [293–
295]. Resilience to AD has been defined as individuals
who exhibit the hallmark neuropathology but no clinical
signs of cognitive imparment [296]. Whereas protection
from disease is defined in GWAS studies (comparing
AD with control subjects) as genetic variants who have
a decreased risk of inheriting the disease, a delay in disease onset, or exhibit less pathology than expected [293].
Potential protective targets include variants in APP that
lead to a reduction in pathologic Aβ [297, 298], APOE
gene variants including APOE2 [251], APOE3-Christchurch [299], and APOE3-Jacksonville [300] with lower
risk of developing AD [301], and variants in cholesterol
efflux pathways such as ABCA1 [302], amongst others
[293]. Identifying potentially protective genetic targets in
human populations may bring to the fore core molecular
mechanisms that can be harnessed for neuroprotective
treatment.
Another novel concept in AD pathology is the possibility that a synergistic pathological interaction exists
between Aβ and tau which manifests throughout the
course of disease and may drive progression [303]. To
date, Aβ and tau proteins have been studied as singular
entities in AD pathophysiology. The study of potential
synergistic relationships between disease-causing elements requires improved animal or cellular models, integrated with systems approaches such as machine learning
to understand such interactions and their spatiotemporal
evolution in disease progression.
Therapeutic opportunities that aid in slowing progression or preventing cognitive decline in AD rely on early
detection of biomarkers associated with early (or prodromal) neurodegenerative events. Although some advances
with blood levels of Aβ and tau have been made recently
[253], robust early markers remain elusive in AD. There
remains great potential in harnessing the eye for early
biomarker detection. The combination of non-invasive
imaging using OCT/OCT-A to detect AD-specific alterations in retinal architecture and morphology with the
detection of Aβ, tau and neurofilament light chain in the
lens, vitreous and retina [304] provides compelling evidence that the eye manifests early AD-related changes
that may be non-invasively detected and monitored in
patients.
Opportunities for new models and imaging systems

In drawing upon the common mechanisms of neurodegenerative diseases, we believe that preventing vision loss
or preventing neurodegeneration of the brain becomes
increasingly achievable. However, identifying and understanding shared molecular mechanisms is only the first
step in designing powerful neuroprotective or neuroreplacement strategies. The next steps rely heavily on the
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validation and rigorous testing of potential neuroprotective or neurorestorative agents, which both involve
robust monitoring of RGCs and neurons in the brain.
With these goals in mind, several immediate challenges
come to the fore.
For major advances in the design and implementation of neuroprotective therapies, the development and
characterization of translatable model systems is critical. In human patients, clinical trials of neuroprotective agents are not a viable option; such studies would
prove high-risk, expensive and involve extensive, perhaps even decades-long trials without easily measurable
outcomes. Without a model system that encapsulates
the multifaceted nature of neurodegenerative disease
(e.g., including multiple cell types in addition to mature
neurons), the development of therapeutic strategies will
repeatedly stall.
A new challenge comes with the recognition that neurodegenerative events, as well as tissue homeostasis, are
not neuron-centric – they are multicellular in nature and
dissecting the roles of multiple cell types is difficult. It
is increasingly evident that glia are important for RGC
maturation, development, and survival [45, 305]. Understanding how glia affect RGCs and other CNS neurons
during development or after injury will be important in
designing neuroprotective drugs, but also in promoting
integration of replacement cells. Harnessing the properties of other cells may promote RGC/neuron survival or
enhance grafting of replacement cells into host tissue.
Likewise, glia, in particular microglia, are central to controlling the development of AD pathology and modulating neuronal activity [59]. Understanding how specific
microglial responses are protective or detrimental can
guide us how to target these cells at different stages of
neurodegenerative diseases.
There is also an urgent need for improved imaging
systems for use in the clinic and in research as we push
forward with neuro-replacement and neuroprotective
strategies. Resolution of the retina at the cellular level will
be fundamental in the assessment of the efficacy of neuroprotective treatments. One example is the detection
of immune cells and assessment of the neuroinflammatory state of the tissue through high resolution imaging. As discussed, neuroinflammation is an over-arching
theme in neurodegeneration. Determining immune cell
infiltration into the retina, or state of glial cell responses
and reactivity would represent a major stride forward
for clinicians and researchers alike when trying to tackle
neuroinflammation in neurodegenerative disease. Similarly, although a distant milestone at present, monitoring
the engraftment of new cells to restore vision or cognitive function will also rely on advanced imaging systems
not yet available. Novel high-resolution in vivo imaging

- Obtaining single cell resolution in vivo.
- Robust, early detection of disease-related biomarkers.
- Most of current detection and diagnosis methods were developed
using participants of Caucasian/euro-centric origin.
- Many patients have comorbid diseases.

3) In vivo imaging tools.

4) Biomarker development.

- Determination of the key prodromal changes and symptoms for each
neurodegenerative disease.
- Larger patient cohorts to generate more robust identification of puta‑
tive biomarkers.
- Improved high-throughput molecular systems to detect changes in
proteins/biofluids/genes.
- Address differences in disease risk stratified by sex, ethnicity, and other
diverse populations.
- Develop biomarkers for differential diagnosis, recruitment, and keeping
in mind cross-disease, co-morbidities for improving clinical trial recruit‑
ment (better representing a diverse population).
- Differential diagnosis amongst different types of glaucoma, Alzheimer’s,
and related dementia, including how to address the common mixed
etiology presentation of dementia.
- Transcriptomic analysis of cell-type specific changes in models of devel‑
opment and degeneration.

- Generation of novel imaging systems that can detect changes at the
cellular level, non-invasively in humans and in animal models.

- Increased understanding of neurovascular coupling mechanisms and
pathways.
- Detection of the changes in the neurovasculature in vivo over time
before and after disease onset.

- Clear understanding of the temporal neurovascular events that con‑
tribute to neurodegenerative disease.

2) Neurovascular breakdown in disease.

Research required
- Increased cellular complexity and modeling of cell-cell interactions over
time.
- Incorporation of vascular elements into multicellular in vitro models.
- Generation of polygenic animal or cellular models of disease.
- Patient-derived in vitro cell and organoid development.
- Address protein isoform and spatiotemporal differences in disease risk
and development (e.g., APOE2/3/4, and insoluble fibril versus soluble/
oligomeric forms of Aβ).
- Epigenetic and ’environmental’ contributions to disease.
- Determine sex-based differences.
- Determine if models are accurately representing manifestations in
human disease.

Current limitation

1) Animal and in vitro disease model development. - Modeling the multifaceted aspect of neurodegenerative disease
in vitro.
- Addressing the polygenic nature of disease in vitro or in animals.
- Translatability of animal models of disease.

Area of opportunity

Table 1 Key areas of research opportunity in neurodegenerative disease. There are four key areas of opportunity in neurodegenerative research, these include animal and
in vitro disease models, neurovascular breakdown, in vivo imaging tools, and biomarker development. The current limitations are outlined and describe the aspects of each
research opportunity that need to be overcome to make progress in the design of novel therapeutics. Finally, we highlight the key areas of research required to overcome current
limitations in the design of novel therapies to treat neurodegenerative disease
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modalities will be necessary to achieve these goals. One
challenge this presents from a research perspective is the
multidisciplinary nature of the expertise required to build
high-resolution imaging systems, and as such, a focus
in the future on multidisciplinary collaborations across
medical and bioengineering fields will be necessary.

Conclusions
The challenge ahead

Providing patients with effective strategies to treat or
prevent neurodegenerative disease is a monumental challenge that scientists and clinicians alike will
increasingly face as the population ages and incidence
of disease increases. Reaching these goals will rely on
a greater understanding of the common pathological
mechanisms across the entire spectrum of neurodegenerative diseases, which include diseases of the brain and
by extension, the visual system. Focusing solely on linking molecular mechanisms to a single disease can lead to
siloed thinking, inability or unwillingness to make major
leaps forward in the development of advanced treatments
and cures applicable to the broader scope of diseases.
In this “think tank” style meeting, with multidisciplinary experts from all aspects of human CNS neurodegeneration, we have identified several common molecular
mechanisms of disease that highlight the most promising
avenues for fruitful collaboration in Table 1. In the diseases touched on in this review, shared mechanisms are
manifold, spanning protein aggregation to mitochondrial dysfunction and altered metabolism, to breakdown
of neuronal-vascular signaling, just as examples. Work to
advance patient treatment and care for neurodegeneration
will need not only to address our understanding of the core
molecular events that occur but also when they occur. We
believe that the commonalities among diseases provide
new and exciting collaborative research opportunities that
we can harness to discover new therapeutics and clinical
strategies.
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